




PHARMACEUTICAL 2017

iBio Inc.
Rank 146 of 292





PHARMACEUTICAL 2017

iBio Inc.
Rank 146 of 292



The relative strengths and weaknesses of iBio Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of iBio Inc. compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 112% points. The greatest weakness of iBio Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 154% points.

The company's Economic Capital Ratio, given in the ranking table, is 78%, being 75% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	23,906
Cost of Goods Sold	0
Intangible Assets	2,092
Liabilities, Current	2,291
Liabilities, Non-Current	0
Other Assets	28
Other Compr. Net Income	-4.0
Other Expenses	0
Other Liabilities	25,265
Other Net Income	-764
Other Revenues	948
Property and Equipment	25,574
Research and Development	3,156
Selling, General and Administrative Expense	7,685

Output Variable	Value in 1000 USD
Assets	51,600
Liabilities	27,556
Expenses	10,841
Revenues	948
Stockholders Equity	24,044
Net Income	-10,657
Comprehensive Net Income	-10,659
Economic Capital Ratio	78%